Interventional Cardiology News and Research

RSS

Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China.

10 Apr 2014

Aortic valve replacement now possible without open-heart surgery

Loyola University Medical Center is the first hospital in Illinois to implant a newly approved aortic heart valve device that does not require open surgery.

From Medtronic 4 Apr 2014

Researcher finds simple blood test that predicts person's risk for sudden cardiac death

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to more quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).

3 Apr 2014

Cardinal Health agrees to acquire AccessClosure for $320 million

Cardinal Health today announced an agreement to acquire privately held AccessClosure Inc., a leading manufacturer and distributor of extravascular closure devices in the United States, for $320 million. Subject to customary closing conditions and regulatory clearances, the all-cash transaction is expected to close by early June 2014.

3 Apr 2014

New standard for U.S. heart transplantation

The Cedars-Sinai Heart Institute has set a new standard for U.S. heart transplantation by completing 117 adult heart transplants and two adult heart-lung transplants, for a total of 119 adult heart transplants in a single year. The previous number set in 2005, was 98 adult heart transplants performed in one year.

18 Mar 2014

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

New class of drugs developed to treat cancer, reduces sudden cardiac death risk after heart attack

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a new class of drugs, originally developed to treat cancer, reduces sudden cardiac death risk after a heart attack. The findings were published online in advance of print in the Journal of the American College of Cardiology.

25 Feb 2014

Getinge secures 78.55% of outstanding shares in Pulsion Medical Systems

Getinge (STO:GETIB) has secured 78.55% of the outstanding shares in Pulsion Medical Systems. All conditions precedent stipulated in the offer document have been met and the transaction was completed yesterday. Pulsion will be consolidated in Getinge's accounts as of March 1 2014.

20 Feb 2014

Tryton Medical received CE Mark for treatment of Left Main Coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it has received CE Mark for the treatment of Left Main Coronary artery disease. With this approval, Tryton Medical becomes the first company to earn a CE Mark for this indication.

13 Feb 2014

FDA approves new artificial heart valve device that does not require major open surgery

An artificial heart valve device that does not require major open surgery has been approved by the Food and Drug Administration.

From Medtronic 5 Feb 2014

Claret receives CE Mark for Sentinel CPS for embolic protection during aortic valve replacement

Claret Medical, Inc., a developer of innovative solutions for cerebral protection during structural heart interventions, vascular interventions, and cardiac surgery procedures, announced that it has received CE Mark for the Sentinel Cerebral Protection System for embolic protection during Transcatheter Aortic Valve Replacement.

28 Jan 2014

Saint Luke receives $3.4M to investigate health benefits, cost-effectiveness of novel cardiac procedures

aint Luke's Mid America Heart Institute has been awarded a $3.4 million, three-year grant from Boston Scientific to investigate and better define the success, safety, health benefits, and cost-effectiveness of novel methods to open challenging blocked coronary arteries previously thought untreatable through minimally invasive techniques.

28 Jan 2014

Toshiba, AHRA announce recipients of 2013 Putting Patients First grant program

Helping facilities develop or improve existing education and patient care initiatives in diagnostic imaging, AHRA: The Association for Medical Imaging Management and Toshiba America Medical Systems, Inc. announced the seven recipients of the sixth annual Putting Patients First grant program. Recipients were judged on their program plan and ability to share best practices for improving patient care and safety in CT, MR, Ultrasound, X-ray and Vascular imaging.

27 Jan 2014

Argon gets FDA clearance to market OptionELITE IVC filter over-the-wire delivery technique

Argon Medical Devices, Inc. announced today that the company has received clearance from the US Food and Drug Administration to begin marketing the OptionELITE retrievable inferior vena cava filter with a new over-the-wire delivery technique.

16 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Tryton Medical launches Bifurcation Institute to advance care for bifurcated coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the launch of the Bifurcation Institute. The Bifurcation Institute is a comprehensive education resource established to advance the standard of care for bifurcated coronary artery disease, a common, and often untreated, clinical need.

19 Dec 2013

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Boston Scientific Corporation and The Medicines Company announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System.

6 Dec 2013

Getinge proposes to acquire Pulsion Medical Systems

Getinge intends to issue a public tender offer to acquire all shares in Pulsion Medical Systems SE ("Pulsion"), listed on the German Stock Exchange (Deutsche Börse).

4 Dec 2013

Siemens Healthcare to introduce new angiography system at RSNA 2013

At the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America, December 1-6 in Chicago, Siemens Healthcare (booth #1934, South Building/Lakeside Center at McCormick Place, Hall A) will introduce a new angiography system optimized for broad clinical utilization.

3 Dec 2013

HeartWare International acquires CircuLite

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has acquired CircuLite, Inc. – developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent.

1 Dec 2013